MedTrace Logo

Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer

NCT00255606 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2013-06-26

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which schedule of docetaxel and prednisone is more effective in treating prostate cancer.

PURPOSE: This randomized phase III trial is studying two different schedules of docetaxel and prednisone to compare how well they work in treating patients with metastatic prostate cancer.

Conditions

Interventions

DRUG

docetaxel

Given in 3- or 4- week courses

DRUG

prednisone

Given in 3- or 4- week courses

Sponsors & Collaborators

  • Tampere University

    lead OTHER

Principal Investigators

  • Pirkko Kellokumpu-Lehtinen · Tampere University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2009-05-31
Completion
2010-08-31

Countries

  • Finland
  • Ireland
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00255606 on ClinicalTrials.gov